Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Trial Details

NCT ID

NCT07329322

Phase

PHASE2

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Sacituzumab Tirumotecan
• Osimertinib

Locations (sample)

• Beijing, China|39.9075,116.39723

Key Eligibility Criteria

• Male or female, ≥ 18 and ≤ 75 years at the time of signing the informed consent form (ICF).
• Histologically or cytologically confirmed NSCLC.
• No prior systemic anti-tumor therapy.
• No prior local therapy for NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.